Cargando…

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer

We compared adjuvant chemotherapy-related myocardial damage by antimyosin scintigraphy in patients who received either nine cycles of FEC (fluorouracil, epirubicin and cyclophosphamide) where the doses of epirubicin and cyclophosphamide were escalated according to the leucocyte nadir (group I, n = 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erselcan, T, Kairemo, K J A, Wiklund, T A, Hernberg, M, Blomqvist, C P, Tenhunen, M, Bergh, J, Joensuu, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374396/ https://www.ncbi.nlm.nih.gov/pubmed/10732745 http://dx.doi.org/10.1054/bjoc.1999.0998

Ejemplares similares

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
por: Cameron, D A, et al.
Publicado: (2003)

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
por: De Placido, S., et al.
Publicado: (1995)

Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer
por: Alıcı, Hayri, et al.
Publicado: (2015)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
por: Bissett, D, et al.
Publicado: (2001)

FEC91 migration FEC vers DSC
por: Serre, C
Publicado: (1990)

FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)

FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)

FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)

FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)

FEC91 Migration FEC vers DSC
por: Serre, C
Publicado: (1990)

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast
por: Harper-Wynne, C, et al.
Publicado: (1999)

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
por: Colleoni, M, et al.
Publicado: (2002)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma
por: Siewert, Jacob M., et al.
Publicado: (2023)

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
por: De Maio, Ermelinda, et al.
Publicado: (2005)

FEC91#15 migration FEC vers DSC
por: Daems, G
Publicado: (1990)

FEC91#26 Migration FEC vers DSC
por: Frammery, B, et al.
Publicado: (1991)

FEC91#27 Migration FEC vers DSC
por: Frammery, B, et al.
Publicado: (1991)

Phase I dose-escalation trial of S-1 combined with carbon-ion radiotherapy for sinonasal squamous cell carcinoma
por: Takahashi, Daiki, et al.
Publicado: (2020)

FEC91
Publicado: (1990)

FEC91
Publicado: (1990)

FEC91
Publicado: (1990)

FEC91
Publicado: (1990)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
por: van der Wall, E., et al.
Publicado: (1996)

FEC91 Migration FEC vers DSC Compte Rendu Reunion
por: Serre, C
Publicado: (1990)

No mutations of FecB and FecG(H) in Iranian Lory sheep
por: Shafieiyan, Zaynab, et al.
Publicado: (2013)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia
por: Levin, Robert D, et al.
Publicado: (2010)

Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer
por: Fan, Chao-Yueh, et al.
Publicado: (2018)

Cardiotoxic Profile and Arterial Stiffness of Adjuvant Chemotherapy for Colorectal Cancer
por: Visvikis, A, et al.
Publicado: (2020)

Conference au FEC
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_mklla84lnkljo435st5mkfb1si